Fostamatinib drug introduction

Fostamatinib (Fostamatinib) is an oral drug that mainly acts on splenic tyrosine kinase (SYK) and is specifically used to treat chronic immune thrombocytopenia (ITP). ITP is a disease caused by an abnormality in the immune system and is characterized by a lower-than-normal number of platelets in the blood, which can cause patients to experience symptoms such as easy bleeding and bruising. Fotantinib promotes platelet production and survival by inhibiting the activity of spleen tyrosine kinase, thereby increasing platelet count and reducing the risk of bleeding.

Fotantinib is considered an important treatment option for ITP patients whose disease has not been effectively controlled by other treatments However, the safety and effectiveness of fotantinib in pediatric patients have not yet been established, and therefore it is generally recommended only for adult patients. Fotantinib is available by prescription, and patients should consult a medical professional before starting treatment.

The recommended starting dose of fotantinib is 100 mg twice daily. During treatment, doctors will adjust the dose based on changes in the patient's platelet count and potential side effects, with the maximum dose being increased to 150 mg twice daily. If the platelet count does not rise significantly enough within 12 weeks to avoid bleeding, your doctor may consider stopping treatment.

The use of fotantinib may cause some adverse reactions, including hypertension, abnormal liver function, severe diarrhea and infection. Among them, high blood pressure is an important concern, so patients need to monitor blood pressure regularly during treatment to ensure that it remains within a safe range. In addition, fotantinib may make patients more susceptible to infections or even worsen existing infections. If a patient experiences serious side effects, the doctor may decide to interrupt or permanently stop the use of fotantinib.

Reference materials:https://www.drugs.com/tavalisse.html